Literature DB >> 1760697

Treatment perspectives in locally advanced unresectable pancreatic cancer.

J Jeekel1, A D Treurniet-Donker.   

Abstract

Locally advanced unresectable pancreatic cancer is sometimes encountered without manifest distant metastases. Twenty patients with histologically proven unresectable pancreatic cancer without distant metastases were treated with radiotherapy and 5-fluorouracil (5-FU). Radiotherapy consisted of 50 Gy external upper abdomen radiation in two courses, concomitant with intravenous 5-FU 375 mg/m2 given as a bolus injection 4-6h before radiation on the first 4 days of each treatment course. The treatment protocol was completed in 18 patients without complications. The median survival time was 10 months which compares favourably with a 3-5 months median survival time when treatment is withheld. Nine patients (45 per cent) were alive at 1 year, two patients at 2, 3 and 4 years. A second-look operation was performed in four patients 6, 11, 12 and 22 months after completion of radiotherapy. In two patients the tumour could be resected. It appears that treatment with radiotherapy and 5-FU may benefit patients with locally advanced unresectable pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1760697     DOI: 10.1002/bjs.1800781121

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  8 in total

1.  The role of chemoradiation therapy in locally advanced pancreatic cancer.

Authors:  Rebekah R White; Srinivas Reddy; Douglas S Tyler
Journal:  HPB (Oxford)       Date:  2005       Impact factor: 3.647

2.  Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group.

Authors:  J H Klinkenbijl; J Jeekel; T Sahmoud; R van Pel; M L Couvreur; C H Veenhof; J P Arnaud; D G Gonzalez; L T de Wit; A Hennipman; J Wils
Journal:  Ann Surg       Date:  1999-12       Impact factor: 12.969

Review 3.  [Therapy of pancreatic adenocarcinoma].

Authors:  M Böhmig; B Wiedenmann; S Rosewicz
Journal:  Med Klin (Munich)       Date:  1999-11-15

Review 4.  Multimodal therapies in ductal pancreatic cancer. The future.

Authors:  K H Link; F Gansauge; J Pillasch; H G Beger
Journal:  Int J Pancreatol       Date:  1997-02

Review 5.  Survival after surgical management of pancreatic adenocarcinoma: does curative and radical surgery truly exist?

Authors:  H G Smeenk; T C K Tran; J Erdmann; C H J van Eijck; J Jeekel
Journal:  Langenbecks Arch Surg       Date:  2004-05-14       Impact factor: 3.445

6.  Is there a place for gastroenterostomy in patients with advanced cancer of the head of the pancreas?

Authors:  G P van der Schelling; R P van den Bosch; J H Klinkenbij; P G Mulder; J Jeekel
Journal:  World J Surg       Date:  1993 Jan-Feb       Impact factor: 3.352

Review 7.  Current approaches to novel therapeutics in pancreatic cancer.

Authors:  Corina E Akerele; Irina Rybalova; Howard L Kaufman; Sridhar Mani
Journal:  Invest New Drugs       Date:  2003-02       Impact factor: 3.850

Review 8.  Combined modality treatment with accelerated radiotherapy and chemotherapy in patients with locally advanced inoperable carcinoma of the pancreas: results of a feasibility study.

Authors:  F J Prott; K Schönekaes; P Preusser; K Ostkamp; W Wagner; O Micke; R Pötter; U Sulkowski; C Rübe; T Berns; N Willich
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.